We have located links that may give you full text access.
Variability in HER2 expression between primary colorectal cancer and corresponding metastases.
Journal of Cancer Research and Clinical Oncology 2018 November
PURPOSE: This study aimed to investigate the HER2 status of primary colorectal cancer (CRC) and corresponding metastases, and determine the correlation between HER2 and clinicopathological characteristics.
METHODS: We collected the clinicopathological features of 98 CRC patients and 66 patients which were previously evaluated for the KRAS status. The tissue samples of primary CRC tumors (n = 98), noninvolved colorectal mucosa (n = 98), paired lymph nodes (n = 98, 69 patients had positive metastatic nodes), and liver metastases (n = 22) were evaluated using immunohistochemistry for HER2. The kappa test was used to evaluate the concordance rate of HER2 status. Survival analysis was established according to the Kaplan-Meier method.
RESULTS: HER2 overexpression was more common in primary tumors among the younger patients (P < 0.05). No survival significance was revealed in the HER2 status. The HER2-positive rate was 11.2% for the primary CRC tumors, 0% for the normal adjacent mucosa tissues, 10.1% for the matched positive lymph nodes, and 31.8% for the corresponding metastasis. Seven of sixty-nine cases (10.1%) exhibited biomarker discordance in nodal metastases compared with primary tumors (κ = 0.48, P < 0.05); 6 out of 22 cases (27.3%) exhibited biomarker discrepancy in liver metastases compared with primary tumors (κ = 0.32, P > 0.05). Compared with lymph nodes, HER2 overexpression in the primary tissue was more common in KRAS wild-type patients (P < 0.05).
CONCLUSIONS: The present study showed a high rate of discordance in matched pairs of primary tumors and metastases, suggesting that the accurate evaluation of HER2 status is essential before any therapeutic decision.
METHODS: We collected the clinicopathological features of 98 CRC patients and 66 patients which were previously evaluated for the KRAS status. The tissue samples of primary CRC tumors (n = 98), noninvolved colorectal mucosa (n = 98), paired lymph nodes (n = 98, 69 patients had positive metastatic nodes), and liver metastases (n = 22) were evaluated using immunohistochemistry for HER2. The kappa test was used to evaluate the concordance rate of HER2 status. Survival analysis was established according to the Kaplan-Meier method.
RESULTS: HER2 overexpression was more common in primary tumors among the younger patients (P < 0.05). No survival significance was revealed in the HER2 status. The HER2-positive rate was 11.2% for the primary CRC tumors, 0% for the normal adjacent mucosa tissues, 10.1% for the matched positive lymph nodes, and 31.8% for the corresponding metastasis. Seven of sixty-nine cases (10.1%) exhibited biomarker discordance in nodal metastases compared with primary tumors (κ = 0.48, P < 0.05); 6 out of 22 cases (27.3%) exhibited biomarker discrepancy in liver metastases compared with primary tumors (κ = 0.32, P > 0.05). Compared with lymph nodes, HER2 overexpression in the primary tissue was more common in KRAS wild-type patients (P < 0.05).
CONCLUSIONS: The present study showed a high rate of discordance in matched pairs of primary tumors and metastases, suggesting that the accurate evaluation of HER2 status is essential before any therapeutic decision.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app